



ASX/Media Release

New Office Address and Contact Details

29 July 2011, Melbourne, Australia: Please be advised that Benitec Limited has a new Principal Place of Business and a new contact phone number effective from 1 August 2011. The previous office phone number will no longer be in use from 31 July 2011. However the registered office has not changed. The new details are as follows:

Phone Contact: +61 (0)2 9555 6986

Fax Contact: +61 (0)3 8678 1342

Principal Place of Business: F6A/1-15 Barr Street
Balmain NSW 2041
Australia

Registered Office: Level 16, 356 Collins Street
Melbourne Vic 3000
Australia

Full details are provided at the Company's website www.benitec.com.

For Further Information

Dr Peter French pfrench@benitec.com
Chief Executive Officer
Tel: +61 (0)412 457 595

About Benitec www.benitec.com

Benitec Limited is developing novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.